Appropriate uptake period for myocardial PET imaging with 18F-FDG after oral glucose loading;Optimaler akquisitionszeitpunkt für die herz-PET mit 18F-FDG nach oraler glukosebelastung

NuklearMedizin

Volumn 42, Issue 1, 2003, Pages 39-44

  Brink, I ^a   Nitzsche, E U ^b   Mix, M ^d   Schindler, T ^c   Hentschel, M ^a   Hogerle S ^a   Moser, E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Abteilung Nuklearmedizin und PET   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

18F FD6 PET; Myocardium; Uptake; Viability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSITRON EMISSION TOMOGRAPHY;

EID: 0037324260     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623904     Document Type: Article

References (34)

1. Bax JJ, Veening MA, Visser FC et al. Optimal metabolic conditions durino fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. Eur J Nucl Med 1997; 24:35-41.
2. Bax JJ, Visser FC, Elhendy A et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med 1999;40:1866-73.
3. Bergmann SR. Use and limitations of metabolic tracers labeled with positron-emitting radionuclides in the identification of viable myocardium. J Nucl Med 1994; 35 (suppl): 15S-22S.
4. Bergmann SR. Cardiac positron emission tomography. Sem Nucl Med 1998;28:320-40.
5. Berry JJ, Baker JA, Pieper Kset al. The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. J Nucl Med 1991;32:1518-25.
6. Brink I, Klenzner T, Krause T et al. Lymph node staging in extracranial head and neck cancer with FDG PET - what is the appropriate uptake period? Nuklearmedizin 2002; 41: 108-13.
7. Choi Y, Brunken RC, Hawkins RA et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993;20:308-18.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
9. Eitzman D, Al-Aouar Z, Kanter HL et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-65.
10. Gambhir SS, Schwaiger M, Huang SC et al.: Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 1989;30:359-66.
11. Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose. J Nucl Cardiol 1994;1:S4-14.
12. Gropler RJ, Siegel BA, Lee KJ et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749-56.
13. 18F]-fluoro-2-deoxy-D-glucose using amino polyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
14. Hasegawa S, Kusuoka H, Uehara T et al. Glucose tolerance and myocardial F-18 fluorodeoxyglucose uptake in normal regions in coronary heart disease patients. Ann Nucl Med 1998;12:363-8.
15. Henrich M, Vester E, Jülicher F et al. Myocardial glucose metabolism in patients with a coronary artery occlusion: a FDG-PET study in the fasted state and after glucose load. J Nucl Med 1991;32:909-14.
16. Knuuti MJ, Nuutila P, Ruotsalainen U et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255-62.
17. Knuuti MJ, Nuutila P, Ruotsalainen U et al. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. J Nucl Med 1993;34:2068-75.
18. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med 2002;29:1257-66.
19. Kofoed KF, Hove JD, Freiberg J et al. Variability of insulin-stimulated myocardial glucose uptake in healthy elderly subjects. Eur J Nucl Med 2002;29:1600-7.
20. Krivokapich J, Huang SC, Selin CE et al. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol 1987, 252:H777-87.
21. Kubota K, Kubota R, Yamada S et al. Reevaluation of myocardial FDG uptake in hyperglycemia. J Nucl Med 1996;37:1713-7.
22. Kubota K, Itoh M, Ozaki K et al. Advantage of delayed whole-body FDG-PET imaging for tumor detection. Eur J Nucl Med 2001;28: 696-703.
23. 18F]FDG to the assessment of myocardial viability. J Cardiovasc Surg 1999, 40:363-72.
24. Lewis P, Nunam T, Dynes A et al. The use of low-dose intravenous insulin in clinical myocardial F-18 FDG PET scanning. Clin Nucl Med 1996;21:15-8.
25. 18F]fluorodeoxyglucose kinetic model in calculations of myocardial glucose metabolism during ischemia. J Nucl Med 1983;24:1064-(??).
26. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol 1997;80:94A-101A.
27. Schäfers M. Methoden und klinische Anwendung der Nuklearkardiologie: Positionsbericht. Nuklearmedizin 2002, 41:3-13.
28. Schelbert HR. Metabolic Imaging to assess myocardial viability. J Nucl Med 1994, 35 (suppl): 8S-14S.
29. Schoder H, Campisi R, Ohtake T et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left venticular contractile dysfunction. J Am Coll Cardiol 199:33:1328-37.
30. Schröder O, Hör G, Hertel A et al. Combined hyperinsulinaemic glucose clampand oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: Comparative results. Nucl Med Comm 1998;19:867-74.
31. 18F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 2001;42:1730-6.
32. Voipio-Pulkki LM, Nuutila P, Knuuti MJ et al. Heart and skeletal muscal glucose disposal in type 2 diabetic patients as determined by positron emission tomography. J Nucl Med 1993, 34:2064-7.
33. vom Dahl J, Altehoefer C, Sheehan FH et al. Effects of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997;38:742-8.
34. Warburg O. The metabolism of tumors. New York: Richard R. Smith Inc. 1931.